BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 10487539)

  • 1. Correlation between acid secretion and proton pump activity during inhibition by the proton pump inhibitors omeprazole and pantoprazole.
    Nishioka K; Nagao T; Urushidani T
    Biochem Pharmacol; 1999 Oct; 58(8):1349-59. PubMed ID: 10487539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in binding properties of two proton pump inhibitors on the gastric H+,K+-ATPase in vivo.
    Shin JM; Sachs G
    Biochem Pharmacol; 2004 Dec; 68(11):2117-27. PubMed ID: 15498502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. By 1023/SK&F 96022: biochemistry of a novel (H+ + K+)-ATPase inhibitor.
    Simon WA; Keeling DJ; Laing SM; Fallowfield C; Taylor AG
    Biochem Pharmacol; 1990 Jun; 39(11):1799-806. PubMed ID: 2160820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restoration of acid secretion following treatment with proton pump inhibitors.
    Shin JM; Sachs G
    Gastroenterology; 2002 Nov; 123(5):1588-97. PubMed ID: 12404233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pantoprazole: a novel H+/K(+)-ATPase inhibitor with an improved pH stability.
    Beil W; Staar U; Sewing KF
    Eur J Pharmacol; 1992 Aug; 218(2-3):265-71. PubMed ID: 1330598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective inhibition of the gastric H+,K(+)-ATPase by omeprazole and related compounds.
    Lorentzon P; Bayati A; Lee H; Andersson K
    Ann N Y Acad Sci; 1997 Nov; 834():592-9. PubMed ID: 9405870
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo.
    Kwon D; Chae JB; Park CW; Kim YS; Lee SM; Kim EJ; Huh IH; Kim DY; Cho KD
    Arzneimittelforschung; 2001; 51(3):204-13. PubMed ID: 11304936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents.
    Besancon M; Simon A; Sachs G; Shin JM
    J Biol Chem; 1997 Sep; 272(36):22438-46. PubMed ID: 9278394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
    Li XQ; Andersson TB; Ahlström M; Weidolf L
    Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of five antisecretory agents acting via gastric H+/K+-ATPase.
    Bastaki SM; Chandranath I; Garner A
    J Physiol Paris; 2000; 94(1):19-23. PubMed ID: 10761684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The H+, K(+)-ATPase inhibitor pantoprazole (BY1023/SK&F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole.
    Simon WA; Büdingen C; Fahr S; Kinder B; Koske M
    Biochem Pharmacol; 1991 Jul; 42(2):347-55. PubMed ID: 1650212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proton pump inhibitors: new drugs and indications.
    Mears JM; Kaplan B
    Am Fam Physician; 1996 Jan; 53(1):285-92. PubMed ID: 8546054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs.
    Uchiyama K; Wakatsuki D; Kakinoki B; Takeuchi Y; Araki T; Morinaka Y
    J Pharm Pharmacol; 1999 Apr; 51(4):457-64. PubMed ID: 10385219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of pentagastrin-stimulated gastric acid secretion by pantoprazole and omeprazole in healthy adults.
    Pratha VS; Hogan DL; Lane JR; Williams PJ; Burton MS; Lynn RB; Karlstadt RG
    Dig Dis Sci; 2006 Jan; 51(1):123-31. PubMed ID: 16416224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Discovery and development of the proton pump inhibitor].
    Igata H; Okabe S
    Nihon Rinsho; 1992 Jan; 50(1):11-7. PubMed ID: 1311779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans.
    Katashima M; Yamamoto K; Tokuma Y; Hata T; Sawada Y; Iga T
    Eur J Drug Metab Pharmacokinet; 1998; 23(1):19-26. PubMed ID: 9625268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The mechanism of action of omeprazole--a survey of its inhibitory actions in vitro.
    Wallmark B; Lorentzon P; Larsson H
    Scand J Gastroenterol Suppl; 1985; 108():37-51. PubMed ID: 2988109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of proton pump inhibitors on thyroid hormone metabolism in rats: a comparison of UDP-glucuronyltransferase induction.
    Masubuchi N; Hakusui H; Okazaki O
    Biochem Pharmacol; 1997 Dec; 54(11):1225-31. PubMed ID: 9416973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.
    Pauli-Magnus C; Rekersbrink S; Klotz U; Fromm MF
    Naunyn Schmiedebergs Arch Pharmacol; 2001 Dec; 364(6):551-7. PubMed ID: 11770010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole.
    Hartmann M; Theiss U; Huber R; Lühmann R; Bliesath H; Wurst W; Lücker PW
    Aliment Pharmacol Ther; 1996 Jun; 10(3):359-66. PubMed ID: 8791964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.